Summary and future perspectives 249 7 58. Reck, M. et al. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J. Clin. Oncol. 37, 537–546 (2019). 59. Peters, S., Reck, M., Smit, E. F., Mok, T. & Hellmann, M. D. How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. Ann. Oncol. 30, 884–896 (2019). 60. Roder, H. et al. Abstract 26: Validation of the Primary Immune Response (PIR) test in advanced non-small cell lung cancer (NSCLC): blinded retrospective analyses from the POPLAR and OAK trials. J. Immunother. Cancer (2021).
RkJQdWJsaXNoZXIy MTk4NDMw